SLAMF7 eiwit (C-His, mens)

SLAMF7

19A, CD319, CRACC, CS1, UNQ576/PRO1138

C-His

< 1.0 EU per μg protein as determined by the LAL method.

1.Flow cytometric analysis of anti-SLAMF7 CAR expression. 5e5 of anti-SLAMF7 CAR-293 cells were stained with 100 μL of 1:50 (2 μL stock solution in 100 μL FACS buffer) of APC-conjugated human SLAMF7 Protein (Site-Specific APC Conjugation, His Tag, Cat. No. 11691-H86H-SA) and negative control protein. Non-transduced 293 cells were used as a control (left) . APC signal was used to evaluate the binding activity (QC tested) . 2.Binding activity of APC-conjugated SLAMF7 protein to PBMC cells. PBMC cells were stained with FITC conjugated anti-CD3 antibody and APC-conjugated human SLAMF7 Protein (Site-Specific APC Conjugation, His Tag, Cat. No. 11691-H86H-SA) and detected by flow cytometry. FITC signal was used to evaluate the content of CD3+ T cells in PBMCs. APC signal was used to evaluate the non-specific binding activity to PBMCs (QC tested) .

Met1-Met226

The protein has a predicted molecular mass of 25.7 kDa.

Human